Katherine L. Nathanson

faculty photo
Associate Professor of Medicine
Member, Abramson Cancer Center, University of Pennsylvania
University Associate/Attending Physician, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia
Member, Center for Research on Reproduction and Women's Health, University of Pennsylvania
Member, Center of Excellence in Environmental Toxicology, University of Pennsylvania
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Co-Leader, Cancer Control Program, Abramson Cancer Center, University of Pennsylvania
Director of Genetics, Basser Research Center, Perelman School of Medicine at the University of Pennsylvania
Chief Oncogenomics Physician, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
Department: Medicine

Contact information
351 BRB II/III
421 Curie Blvd
University of Pennsylvania
Philadelphia, PA 19104
Office: 215-662-4740
Education:
B.A. (Biology)
Haverford College, Haverford, PA, 1987.
M.D.
University of Pennsylvania, Philadelphia, PA, 1993.
Permanent link
 

Description of Research Expertise

Dr. Nathanson’s research focuses on the genetics of human cancer, both germline changes which confer susceptibility to cancer and somatic genetic changes associated with outcome.

Her research projects fall into several areas:

1) Identification and characterization of germline genetic changes associated with breast cancer susceptibility. These projects utilize two sample sets, a large clinical database of high risk breast cancer patients and a case-control study of white and black patients with breast cancer. Currently the projects in the laboratory focus on resequencing of BRCA1-associated genes as candidate breast cancer susceptibility genes in patients with high risk breast cancer and studying copy number variation as associated with potential susceptibility to high risk breast cancer in families with multiple cases of breast cancer.

2) Identification of genetic changes associated with testicular cancer susceptibility in case-control sample set. Dr. Nathanson recently completed a successful genome wide association study in testicular cancer, and is in the process of designing and doing a number of follow-up studies.

3) Identification of somatic genetic markers in melanoma as determinants of response to therapy. The projects in the laboratory focus on several aspects of melanoma genetics including genotyping patients to determine targeted therapy selection, using genetics and genomics to sub-set melanomas, as well as understand response to therapy, and identify novel genes important in melanoma progression.

Description of Itmat Expertise

Dr. Nathanson is studying the inherited and somatic genetics of cancer, including: 1) Identification of genetic changes associated with an increased risk of breast cancer and testicular germ cell tumors; 2) high throughput characterization of multiple tumor types using array based comparative genomic hybridization, mutation and expression profiling; and 3) identification of somatic and inherited genetic changes relating to outcomes in clinical trials of cancer, specifically melanoma and renal cancer.

Selected Publications

Domchek SM, Nathanson KL: Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. Genet Med Jul 2014.

Koster R, Mitra N, D'Andrea1 K, Vardhanabhuti S, Chung CC, Wang Z, Erickson RL, Vaughn DJ, Litchfield K, Rahman N, Greene MH, McGlynn KA, Turnbull C, Chanock SJ, *Nathanson KL, *Kanetsky PA: Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. Hum Molec Genet Jun 2014 Notes: *These authors co-directed this study.

Wilson MA, Zhao F, Letrero R, D’Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL: Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib. Clin Cancer Res 20(12): 3328-3337, Jun 2014.

Rangwala R, Leone R, Chang YC, Fecher L, Schuchter L, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel A, Evans T, Demichele A, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10(8), May 2014.

Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff M, Wubberhorst B, Kim SB, Kopetz S, Ledoux A, Vashisht Gopal YN, Goncalves Pereira C, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA : Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res Page: [Epub ahead of print] May 2014.

Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, Swe-Brca, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Ejlertsen B, Gerdes AM, Infante M, Herráez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodríguez G, Brewster W, Wakeley K, Rutherford T, Caldés T, Nevanlinna H, Aittomäki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Hoogerbrugge N, Collée JM, van Deurzen CH, van der Luijt RB, Devilee P, Hebon, Olah E, Lázaro C, Teulé A, Menéndez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, Investigators K, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowicz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J: DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genet 10(4): e1004256, Apr 2014.

Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M: MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 33(14): 1850-1861, Apr 2014.

Kumar SM, Dai J, Li S, Yang R, Yu H, Nathanson KL, Liu S, Zhou H, Guo J, Xu X: Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation. Oncogene 33(7): 832-841, Feb 2014.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC: Restricted expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Carcinomas enhances HIF2α activity. Cancer Discov 4(1): 53-60, Jan 2014.

Curry JL, Davies MA, Calderone TL, Nathanson KL, Prieto VG, Gershenwald JE: Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol(1102), 679-695, 2014.

back to top
Last updated: 07/23/2014
The Trustees of the University of Pennsylvania